×
We couldn’t find any recent recommendations for this company (matched by symbol or BSE code). Please check back later.
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.09 | 84.8 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| JENBURKT PHARMACEUTICALS LTD. | NA | NA | NA | NA | 475.0 | 14.6 |
| OXYGENTA PHARMACEUTICAL LIMITE | NA | NA | NA | NA | 456 | |
| ALBERT DAVID LTD. | 926.03 | 79.38 | 705.66 | 13.91 | 443 | 70.5 |
Jenburkt Pharmaceuticals Ltd., with Security Code 524731, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34.6 | 35.2 | 29.2 | 38.3 | 35.7 | 38.8 | 32.5 | 41.2 | 36.9 | 41.0 |
| Expenses | 27.6 | 27.7 | 22.2 | 29.2 | 28.5 | 29.0 | 23.2 | 29.8 | 28.1 | 30.1 |
| Operating Profit | 7.0 | 7.5 | 7.0 | 9.1 | 7.2 | 9.9 | 9.3 | 11.4 | 8.8 | 10.9 |
| OPM % | 20.19% | 21.3% | 23.88% | 23.78% | 20.18% | 25.36% | 28.55% | 27.72% | 23.91% | 26.67% |
| Other Income | 1.5 | 1.3 | 1.0 | 1.1 | 1.3 | 1.2 | 1.4 | 1.9 | 1.6 | 1.9 |
| Interest | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Depreciation | 0.6 | 0.6 | 0.5 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.8 | 0.8 |
| Profit before tax | 7.8 | 8.1 | 7.4 | 9.5 | 7.8 | 10.4 | 10.1 | 12.5 | 9.5 | 11.9 |
| Tax % | -29.9% | -21.3% | -27.7% | -23.3% | -31.1% | -24% | -26.3% | -23.3% | -31.6% | -27% |
| Net Profit | 5.4 | 6.4 | 5.4 | 7.3 | 5.4 | 7.9 | 7.4 | 9.6 | 6.5 | 8.5 |
| EPS in Rs | 11.84 | 13.92 | 12.17 | 16.59 | 12.25 | 17.86 | 16.8 | 21.75 | 14.75 | 0 |
No Consolidated data available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 5% |
| 3 Years: | 7% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| TTM: | 24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 30% |
| 3 Years: | 28% |
| 1 Year: | 46% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 0% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| 1 Year: | 0% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| News Date ▲▼ | Headline ▲▼ | Issuer Entity ▲▼ | Issuer Type ▲▼ | Order Size ▲▼ | Time Period ▲▼ | |
|---|---|---|---|---|---|---|
| Loading company updates… | ||||||
We couldn’t find any filings or updates in the Company News collection for this BSE code.
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|